Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Oct 2000
Clinical TrialA phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer.
Docetaxel is an active agent used in the treatment of non-small cell lung cancer (NSCLC). ⋯ Docetaxel is active and has an acceptable toxicity profile, in both first- and second-line treatments, in Chinese patients with inoperable NSCLC.